Valuation: Theralase Technologies Inc.

Market Cap 76.87M 54.56M 47.88M 44.59M 41.01M 5.21B 78.19M 529M 207M 2.58B 205M 200M 8.93B P/E 2026 *
-26x
P/E 2027 * 13x
Enterprise Value 76.87M 54.56M 47.88M 44.59M 41.01M 5.21B 78.19M 529M 207M 2.58B 205M 200M 8.93B EV / Sales 2026 *
95.9x
EV / Sales 2027 * 2.27x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week+1.92%
Current month+3.92%
1 month+10.42%
3 months-18.46%
6 months+1.92%
Current year+60.61%
1 week 0.26
Extreme 0.255
0.28
1 month 0.23
Extreme 0.23
0.28
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Buy

Director

20,900 0.0081%
20/05/26 Sell

Director

20,900 0.0081%
20/05/26 Sell

Director

-65,973 0.0257%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%+1.92%+35.90%-10.17% 54.47M
+0.39%-3.76%+24.35%+41.14% 1.4B
0.00%-3.65%-14.23%-51.94% 50.99M
Average +0.77%-1.49%+15.34%-6.99% 500.43M
Weighted average by Cap. +0.43%-4.64%+23.46%+36.12%

Financials

2026 *2027 *
Net sales 802K 569K 500K 465K 428K 54.38M 816K 5.52M 2.16M 26.97M 2.14M 2.09M 93.17M 33.89M 24.05M 21.11M 19.65M 18.08M 2.3B 34.47M 233M 91.27M 1.14B 90.29M 88.34M 3.94B
Net income -4.2M -2.98M -2.62M -2.44M -2.24M -285M -4.27M -28.9M -11.31M -141M -11.19M -10.95M -488M 6.83M 4.85M 4.25M 3.96M 3.64M 463M 6.95M 47M 18.4M 230M 18.2M 17.81M 794M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
28/07/26 CA$0.2650 +1.92% 502
27/07/26 CA$0.2600 -1.89% 18,519
24/07/26 CA$0.2650 +1.92% 79,502
23/07/26 CA$0.2600 0.00% 22,559
22/07/26 CA$0.2600 0.00% 16,500
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2600CAD
Average target price
0.7000CAD
Spread / Average Target
+169.23%

Quarterly revenue - Rate of surprise